Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameAscletis-B
Stock Code01672
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities歌禮是一個一體化抗病毒平台,專注於開發及商業化針對丙肝、HIV和乙肝的創新的、同類最佳的藥物,涵蓋從發現和開發到生產和商業化的整個價值鏈。
Listing Date2018-08-01
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國浙江省杭州市濱江區江漢路1785號雙城國際4幢18層
Business Address (Hong Kong)香港灣仔皇后大道東28號金鐘匯中心18樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.ascletis.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 14.00 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2018-07-20 to 2018-07-25
Global Offering Shares224,137,000 shares
HK Public Offer Shares (Initial)22,414,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)201,723,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,120,685,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share18.8%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 3,137,918,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 11.36B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status2017年虧損人民幣86.9百萬元
Period-End Cash Balance人民幣607.4百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO Investment1.55億美元

Financial Data

Unit: '000 RMB
Income Statement
Item 201620172018-03
Revenue 32,97653,20251,062
Gross profit 32,97653,20251,062
Other income and gains, net 14,49649,5936,437
Administrative expenses -15,044-37,477-15,717
Profit before tax -31,873-80,441-983
Income tax expense -6,490125
Profit for the year -31,873-86,931-858
Profit attributable to owners -26,807-53,93511,629
Balance Sheet
Item 201620172018-03
Cash and cash equivalents 418,973607,367526,022
Inventories 18,74762,21169,188
Total current assets 466,008875,618773,636
Total current liabilities 73,39999,22867,899
Total equity 409,084869,831799,937
Equity attributable to owners 272,359596,961597,341
Cash Flow Statement
Item 201620172018-03
Net cash from operating activities -12,498-198,056-45,741
Net cash from investing activities -37,633-644,542170,526
Net cash from financing activities 88,159549,362-57,815
Net increase in cash 38,028-293,23666,970
Depreciation of PP&E 5792,108586
Amortisation of intangible assets 1,8923,442978
Purchase of PP&E -44,606-15,298-2,854
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 14.0
First Day OpenHK$ 14.8
First Day Change19.57%
First Day Volume82741300.0
First Day Turnover1179890000.0
Use of Proceeds
1、約30.0%或892.8百萬港元將用于我們核心產品線的持續研發; 2、約25.0%或744.0百萬港元將用于戈諾衛及拉維達韋商業化; 3、約15.0%或446.4百萬港元將用于尋求新在研藥物的引進許可,盡管我們截至最后實際可行日期尚未物色到任何潛在目標; 4、約10.0%或297.6百萬港元將用于通過啟動及進行臨床試驗進行ASC21的研發; 5、約10.0%或297.6百萬港元將用于支持我們的研發基礎設施及HBV及NASH發現階段兩個內部藥物計劃的早期開發; 6、約10%或297.6百萬港元將用于我們的營運資金及作其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (3)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Overall Coordinators (3)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Bookrunners (3)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Lead Managers (3)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 GIC Private Limited 588,588,000 HKD — 18.76% — 6 months 2019-02-01

Directors & Management

PositionChinese nameEnglish Name
Chairman吳勁梓—
Company Secretary王漸炯、嚴洛鈞—
No director data available.

Major Shareholders

Major Shareholders & Holdings吳博士及吳夫人合共持有約53.29%股權;JJW11 Limited持有5.80%;CBC Investment Twelve Limited持有5.93%;CBC Investment Fifteen Limited持有6.45%。
About this page

This page shows Ascletis-B (01672) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect